ArticleBMJ open2024

Study protocol for a randomised, phase II, double-blind, experimental medicine study of obinutuzumab versus rituximab in ANCA-associated vasculitis: ObiVas.

Dominic Paul McGovern et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.